9-Octadecenoic acid (Z)-, isooctyl ester, reaction products with glycerol trioleate and sulfur

Repeated dose toxicity: oral

Administrative data

Endpoint:

short-term repeated dose toxicity: oral

Remarks:

combined repeated dose and reproduction / developmental screening

Type of information:

migrated information: read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

weight of evidence

Reliability:

4 (not assignable)

Rationale for reliability incl. deficiencies:

other: see 'Remark'

Remarks:

The assessment is not possible to rate as it is based on published robust study summaries rather than the actual study reports. The authors consider the key study with CAS# 61789-01-3 Fatty acids, tall-oil, epoxidized, 2-ethylhexyl esters to be reliable without restriction.

Data source

Reference

Reference Type:

publication

Title:

Unnamed

Year:

2006

Report date:

2005

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)

GLP compliance:

yes

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Fatty acids, tall-oil, epoxidized, 2-ethylhexyl esters

EC Number:

263-024-2

EC Name:

Fatty acids, tall-oil, epoxidized, 2-ethylhexyl esters

Cas Number:

61789-01-3

IUPAC Name:

61789-01-3

Details on test material:

Fatty acids, tall-oil, epoxidized, 2-ethylhexylesters, 100% pure

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

None provided, but the study was considered a Klimisch 1 study so deviations from OECD protocol are not expected.

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

corn oil

Duration of treatment / exposure:

Males: at least 28 days
Females: 14 days prior to pairing, throughout pregnancy until postnatal day 4

Frequency of treatment:

Daily

Doses / concentrations

Remarks:

Doses / Concentrations:
0, 100, 300, 1000
Basis:
actual ingested

Results and discussion

Results of examinations

Details on results:

No test article-related mortalities or clinical signs were noted throughout the study. None of the parameters under investigation during the functional observational battery gave any indication of test item-related effects. Neither food consumption nor body weight development was affected by treatment with the test article at any dose level. The assessment of clinical chemistry and hematology parameters indicated no differences between animals treated with test article and vehicle controls. During necropsy of parent animals no test article-realted findings were noted. For males treated at 300 and 1000 mg/kg bw/d, mean absolute and relative liver weights were dose-dependently increased. For females treated at 1000 mg/kg bw/d, mean absolute and relative liver weights were increased. Histopathological findings included the following:
LIVER: Minimal hepatocellular hypertrophy in animals treated at 1000 mg/kg bw/d. This change was considered to represent an adaptive reaction most likely induced by an increased biotransformation of the test article. This was not considered an adverse effect.
THYROID: Increased incidence of minimal follicular cell hypertrophy in animals treated with 1000 mg/kg bw/d.

Effect levels

Dose descriptor:

NOAEL

Effect level:

1 000 mg/kg bw/day (actual dose received)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

other: No test article-related mortalities or clinical signs were noted throughout the study.

Target system / organ toxicity

Critical effects observed:

not specified

Applicant's summary and conclusion

Conclusions:

No studies were available for the registered substance. An OECD 422 study is available for the analagous substance, CAS # 61789-01-3. No test article related adverse signs of toxicity were observed for this substance and the NOAEL was determined to be 1000 mg/kg bw/day.

Executive summary:

No studies were available for the registered substance. An OECD 422 study is available for the analagous substance, CAS # 61789-01-3 (ETP). No test article related adverse signs of toxicity were observed for this substance and the NOAEL was determined to be 1000 mg/kg bw/day. ETP was administered once daily orally (by gavage) to male rats for at least for 28 days and to female rats throughout the 14 day pre-pairing period, throughout pairing and gestation up to lactation day 4 according to OECD Guideline 422 (RCC, 2005b). The dose levels were 0 (vehicle control), 100, 300 and 1000 mg/kg bw/d. No test article-related mortalities or clinical signs were noted throughout the study. None of the parameters under investigation during the functional observational battery gave any indication of test item-related effects. Neither food consumption nor body weight development was affected by treatment with ETP at any dose level. The assessment of clinical chemistry and hematology parameters indicated no differences between animals treated with ETP and vehicle controls. During necropsy of parent animals no test article- related findings were noted. For males treated at 300 and 1000 mg/kg bw/d, mean absolute and relative liver weights were dose-dependently increased. For females treated at 1000 mg/kg bw/d, mean absolute and relative liver weights were increased. Histopathological findings included the following: Minimal hepatocellular hypertrophy in animals treated at 1000 mg/kg bw/d. This change was considered to represent an adaptive reaction most likely induced by an increased biotransformation of the test article. This was not considered an adverse effect. Increased incidence of minimal follicular cell hypertrophy in the thyroid of animals treated with 1000 mg/kg bw/d. The NOAEL for ETP in this repeat dose toxicity study was considered to be 1000 mg/kg bw/d.